Nuvalent, Inc. (NUVL)
Health Care ยท Pharmaceutical Preparations
Nuvalent, Inc. (NUVL) was listed on Nasdaq from July 29, 2021. SentiSense covers Nuvalent, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. James Porter is its chief executive officer. The company reports 228 employees, and its corporate website is www.nuvalent.com.
About Nuvalent, Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Latest reported results
Nuvalent Inc. Class A reported revenue of $0.00 for Q1 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 282 institutions reported holding NUVL, with 75.2 million shares worth $9.3 billion in aggregate. The largest reported holders were Deerfield Management Company, Paradigm Biocapital Advisors and BlackRock. Of the 5 largest reported holders, 1 opened a new position in NUVL, 3 added shares and 1 held its position unchanged during the quarter.
More on NUVL
- NUVL sentiment: whether news and social coverage of Nuvalent, Inc. leans bullish or bearish, and the stories driving it.
- NUVL ownership: all 282 reporting institutions, plus insider and congressional trades.
- NUVL financials: revenue, net income, operating margin and free cash flow through Q1 FY2026.
Frequently asked questions
What does Nuvalent, Inc. do?
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.
What sector is NUVL in?
SentiSense classifies Nuvalent, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where did NUVL stock trade?
Nuvalent, Inc. (NUVL) was listed on Nasdaq from July 29, 2021.
Who is the CEO of Nuvalent, Inc.?
James Porter is the chief executive officer of Nuvalent, Inc..